Definitions

1. Sclerosis is the name of the condition, which results from the degeneration of such elements of the nervous system as the myelin sheath. (Web site)
2. Sclerosis is the main feature in the skull.
3. Sclerosis is most specific for disease that involves the cricoid and arytenoid cartilages and least specific for tumor that invades the thyroid cartilage. (Web site)
4. Multiple sclerosis (MS) is a disease of the central nervous system (CNS), the nerves that comprise the brain and spinal cord.
5. Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) in which the immune system can attack the brain and spinal cord. (Web site)

Secondary Progressive

1. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
2. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis.
3. BACKGROUND: Treatment options for patients with secondary progressive multiple sclerosis are few. (Web site)

Progressive Systemic Sclerosis

1. Cyclosporine in the treatment of progressive systemic sclerosis: clinical and immunological findings.
2. Increase in fibronectin in the deep dermis of involved skin in progressive systemic sclerosis. (Web site)

Relapsing-Remitting

1. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis.
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. (Web site)
3. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis.

Tuberous Sclerosis Gene

1. Currently, there is no test to identify a person who has the tuberous sclerosis gene if that person has no signs or symptoms of it. (Web site)
2. If a parent has tuberous sclerosis gene, each offspring has a 50 percent chance of developing the disorder. (Web site)
3. Thus incidental detection of subependymal nodules raise suspicion of tuberous sclerosis gene in the family or it may be due to some mutation.

Faecal Incontinence

1. Nicholls RJ, Sacral nerve stimulation for faecal incontinence due to systemic sclerosis.
2. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. (Web site)

Systemic Sclerosis

1. High incidence of Helicobacter pylori infection in patients with systemic sclerosis: association with Sicca Syndrome.
2. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. (Web site)
3. Cyclosporine in systemic sclerosis. (Web site)

Matter Changes

1. Filippi M, Tortorella C, Bozzali M. Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. (Web site)

Hippocampal Sclerosis

1. Aug 29;[Epub ahead of print] Hippocampal sclerosis in temporal lobe epilepsy (TLE) is often associated with hippocampal atrophy.
2. Hippocampal sclerosis in temporal lobe epilepsy demonstrated by magnetic resonance imaging. (Web site)
3. Temporal lobe epilepsy due to hippocampal sclerosis in pediatric candidates for epilepsy surgery.

Amyotrophic Lateral Sclerosis

1. High aluminum deposition in the central nervous system of patients with amyotrophic lateral sclerosis from the Kii Peninsula, Japan: two case reports.
2. Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis.
3. Stober T, Stelte W, Kunze K. 1983. Lead concentrations in blood, plasma, erythrocytes, and cerebrospinal fluid in amyotrophic lateral sclerosis.

Calcify

1. These lesions mimic the appearance of the subependymal tubers in tuberous sclerosis, although they do not calcify. (Web site)
2. The name tuberous sclerosis comes from the characteristic tuber or root-like growths in the brain, which calcify with age and become hard or sclerotic. (Web site)

Tuberous Sclerosis

1. Tuberous sclerosis derives its name from the tuber-like growths on the brain which calcify with age and become hard or sclerotic.
2. This type of low-grade glioma is common in patients with a disease called tuberous sclerosis.
3. The first signs of tuberous sclerosis may be seizures and spots on the skin. (Web site)

Lyme Disease

1. Viral or bacterial causes have been substantiated in multiple sclerosis, Parkinson's disease, Lyme disease, encephalopathy, and encephalomyelitis.

Gliosis

1. We included 114 patients who had mesio-temporal lobe epilepsy and hippocampal sclerosis or gliosis on histology.

Cerebral Cortex

1. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. (Web site)

Degeneration

1. This may result from ischemia or from degeneration (ie, sclerosis) of the sinoatrial (SA) node or atrioventricular (AV) conducting system.

Plaques

1. The formation of plaques can cause nerve fibers in the brain and spine to harden, a process known as sclerosis. (Web site)
2. Quantitative magnetic resonance imaging of brainstem volumes, plaques, and surface area in the occipital regions of patients with multiple sclerosis.

Skin

1. Between 60 and 90 percent of infants with tuberous sclerosis have white patches or spots (hypomelanotic macules) on their skin at birth.
2. Tuberous sclerosis affects many organs in the body including the brain, spinal cord, lungs, heart, kidneys, skin, and skeletal bones in the child.
3. Tuberous sclerosis is a rare genetic, neurological disorder primarily characterized by seizures, mental retardation, and skin and eye lesions. (Web site)

Symptomatic

1. The treatment for tuberous sclerosis is supportive and symptomatic.

Analysis

1. Analysis of cerebrospinal fluid may show changes characteristic of multiple sclerosis or Kearns-Sayre syndrome.

Correlation

1. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. (Web site)
2. MR imaging quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing. (Web site)
3. Correlation with Other Symptoms Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases.

Immune System

1. They are used to treat diseases that involve the immune system such as certain types of cancer, hepatitis, multiple sclerosis, and genital warts.
2. Sometimes spinal fluid can indicate diseases of the immune system, such as multiple sclerosis.

Aids

1. Avoid with a history of conditions affecting the immune system (such as AIDS, HIV, some types of cancer, multiple sclerosis, tuberculosis, or lupus).

Astrocytes

1. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis.

Gray Matter

1. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. (Web site)

Spinal Cord Injury

1. A higher incidence of the condition is observed in patients with Parkinson disease, multiple sclerosis, or spinal cord injury.
2. This is most useful in stroke, spinal cord injury, multiple sclerosis and motor neuron disease. (Web site)
3. This is most useful in monitoring stroke, spinal cord injury, multiple sclerosis and motor neuron disease. (Web site)

Brain Tumors

1. The most common pathologies found were brain tumors, mesial temporal sclerosis and developmental lesions. (Web site)

Benign

1. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. (Web site)

Suspected

1. Tuberous sclerosis should be suspected in patients who have one major feature or two or more minor features. (Web site)
2. If multiple sclerosis is suspected, a special x-ray test of the brain, called a cranial MRI, may be ordered.

Clinically

1. Patients who have tuberous sclerosis may have already presented clinically with seizures or mental retardation.
2. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. (Web site)

Result

1. Comas can result from injuries, such as head trauma or stroke, or from complications of an illness like multiple sclerosis. (Web site)
2. For example, cerebral vascular accidents, multiple sclerosis, Parkinson's disease, and spinal cord injury may result in neurogenic erectile dysfunction.
3. Mutations of at least two different genes are known to result in tuberous sclerosis.

Results

1. Surgical treatment of epilepsy in tuberous sclerosis: strategies and results in 18 patients. (Web site)
2. Multiple sclerosis is a neurological disorder that results from abnormal demyelination of peripheral nerves.
3. This results in slowing or blocking the transmission of nerve impulses in that area, leading to the symptoms of multiple sclerosis. (Web site)

Trauma

1. Localized weakness may follow a stroke, exacerbation of multiple sclerosis, or trauma to a motor nerve root or peripheral nerve.

Incidence

1. A slightly increased incidence of renal cell carcinomas has been noted in patients with tuberous sclerosis. (Web site)
2. Brain. 1956 Dec; 79(4):635–654. [ PubMed] SWANK RL. Multiple sclerosis; a correlation of its incidence with dietary fat.
3. Vitamin D intake and incidence of multiple sclerosis. (Web site)

Prevalence

1. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. (Web site)
2. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint).
3. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. (Web site)

Injury

1. Localized weakness may follow a stroke, flare up of multiple sclerosis, or injury to a nerve.

Suffering

1. By the mid-1970s, Mingus was suffering from Amyotrophic lateral sclerosis (popularly known as Lou Gehrig 's disease) a wastage of the musculature. (Web site)
2. By the mid-1970s, Mingus was suffering from amyotrophic lateral sclerosis, popularly known as Lou Gehrig's disease, a wastage of the musculature.

Trial

1. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. (Web site)

Randomised

1. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Strokes

1. Central neuropathic pain is found in spinal cord injury, multiple sclerosis, and some strokes. (Web site)
2. Can be used in the diagnosis and monitoring of brain tumors, strokes, multiple sclerosis and other conditions.

Product

1. The product is approved in Canada as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis, and for cancer related pain. (Web site)
2. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. (Web site)
3. Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. (Web site)

Aspartame

1. Aspartame and Multiple Sclerosis - Neurosurgeon's Warning Aspartame is a low calorie sweetener. (Web site)
2. Unfortunately the Multiple Sclerosis society denies there is any connection between MS and Aspartame. (Web site)

Diabetes

1. At the molecular level, lymphocytes in aplastic anemia show similarity to T cells in multiple sclerosis, diabetes, and other related illnesses.
2. Multiple sclerosis (MS). AIDS. Diabetes and blood sugar problems. (Web site)
3. Disorders such as diabetes, systemic sclerosis, and amyloidosis also can slow peristalsis, causing bacterial overgrowth. (Web site)

Cure

1. Electrical stimulation does not cure multiple sclerosis nor does it prevent the disease from getting worse. (Web site)
2. The National Multiple Sclerosis Society is the only voluntary health organization dedicated to the prevention, treatment, alleviation, and cure of MS.
3. Tuberous sclerosis complex has no cure at present. (Web site)

Tumor

1. Call a geneticist if your child is diagnosed with cardiac rhabdomyoma, as tuberous sclerosis is the leading cause of this tumor. (Web site)
2. This tumor is often seen in children and some adults with a condition called Tuberous Sclerosis.

Progression

1. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.
2. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. (Web site)
3. Oxidative stress has been implicated in the progression of Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. (Web site)

People

1. Multiple Sclerosis: People with denture adhesive neuropathy are often suspected to be suffering from Multiple Sclerosis.
2. The main purpose of deep brain stimulation for people with multiple sclerosis is to control the tremor related to the disease.
3. These cases occur in people with no history of tuberous sclerosis in their family. (Web site)

Categories

1. Anatomy > Neuroanatomy > Nervous System > Central Nervous System
2. Humans > Health > Diseases > Patients
3. Placebo-Controlled Trial
4. Humans > Medicine > Anatomy > Brain
5. Myelin

Related Keywords

* Ann Romney * Associated * Atrophy * Autism * Autoimmune * Autoimmune Disorder * Brain * Brainstem * Brain Atrophy * Central Nervous System * Clinical Signs * Demyelination * Diabetic Neuropathy * Diagnosis * Disability * Disease * Diseases * Disorder * Disorders * Donnycarney * Double-Blind * Epilepsy * Family History * Grey Matter * Hippocampus * Individuals * Lesion * Lesions * Lupus * Magnetic Resonance Imaging * Matter * Mesial Temporal Sclerosis * Mitoxantrone * Motor Impairment * Mri * Mutations * Myelin * Natalizumab * Nerves * Nerve Cells * Nervous System * Neurons * Optic Neuritis * Parkinsonism * Pathogenesis * Patients * Placebo-Controlled * Placebo-Controlled Trial * Progressive * Randomized * Relapsing * Rheumatoid Arthritis * Scarring * Sclerosis Lesions * Sclerosis Patients * Seizures * Spasticity * Spinal Cord * Spinal Cord Injuries * Stroke * Study * Sutton * Symptoms * Temporal Lobe * Temporal Lobe Epilepsy * Treatment * Tremor * Tuberous Sclerosis Complex * Tumors

1. Books about "Sclerosis" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -